JP2009517412A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517412A5
JP2009517412A5 JP2008542573A JP2008542573A JP2009517412A5 JP 2009517412 A5 JP2009517412 A5 JP 2009517412A5 JP 2008542573 A JP2008542573 A JP 2008542573A JP 2008542573 A JP2008542573 A JP 2008542573A JP 2009517412 A5 JP2009517412 A5 JP 2009517412A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
alkyl group
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008542573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001963 external-priority patent/WO2007062526A1/en
Publication of JP2009517412A publication Critical patent/JP2009517412A/ja
Publication of JP2009517412A5 publication Critical patent/JP2009517412A5/ja
Pending legal-status Critical Current

Links

JP2008542573A 2005-11-30 2006-11-30 アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法 Pending JP2009517412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74064205P 2005-11-30 2005-11-30
PCT/CA2006/001963 WO2007062526A1 (en) 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation

Publications (2)

Publication Number Publication Date
JP2009517412A JP2009517412A (ja) 2009-04-30
JP2009517412A5 true JP2009517412A5 (enExample) 2009-12-17

Family

ID=38091843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542573A Pending JP2009517412A (ja) 2005-11-30 2006-11-30 アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法

Country Status (8)

Country Link
US (2) US8227450B2 (enExample)
EP (1) EP1971615B1 (enExample)
JP (1) JP2009517412A (enExample)
CN (1) CN101405293B (enExample)
AU (1) AU2006319716B2 (enExample)
CA (1) CA2632095A1 (enExample)
ES (1) ES2452718T3 (enExample)
WO (1) WO2007062526A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
JP2009517412A (ja) 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
AU2007287353A1 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10369129B2 (en) 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
WO2017209732A1 (en) * 2016-05-31 2017-12-07 Taimed Biologics, Inc. A long acting pharmaceutical composition of protease inhibitor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013861A (en) 1985-02-28 1991-05-07 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
JPH06501950A (ja) 1990-10-11 1994-03-03 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 環状ペプチド、その調製法およびその薬理組成物としての使用
US5614522A (en) 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0656888B1 (en) 1992-08-25 1998-01-07 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6022994A (en) 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5463104A (en) 1992-08-25 1995-10-31 G. D. Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JPH06321950A (ja) 1993-05-14 1994-11-22 Takeda Chem Ind Ltd 水溶性ランカシジン誘導体
WO1995006998A1 (en) 1993-08-31 1995-03-09 Stanley Kugell Telephone billing method
WO1995024385A1 (en) 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2303337T3 (es) 1995-01-20 2008-08-01 G.D. Searle Llc Inhibidores de la proteasa retroviral de bis-hidroxietilamino sulfonamida.
US5985870A (en) 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2000501111A (ja) 1996-01-26 2000-02-02 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼインヒビター
AU720615B2 (en) 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
PT877019E (pt) 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EE200000386A (et) * 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
ATE311391T1 (de) 1999-02-12 2005-12-15 Vertex Pharma Aspartyl-protease-inhibitoren
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6656968B1 (en) * 1999-06-16 2003-12-02 Temple University - Of The Commonwealth System Of Higher Education (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors
US6506786B2 (en) 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
EP1480941B1 (en) 2002-03-04 2011-01-26 Ambrilia Biopharma Inc. Urea derivatives as hiv aspartyl protease inhibitors
CA2374362C (en) 2002-03-04 2008-01-22 Brent Richard Stranix Urea derivatives as hiv aspartyl protease inhibitors
PL376900A1 (pl) 2002-12-16 2006-01-09 Boehringer Ingelheim International Gmbh Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
AU2004312284B2 (en) 2004-01-08 2010-08-05 Medivir Ab Non-nucleotide reverse transcriptase inhibitors
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ATE417823T1 (de) 2004-08-02 2009-01-15 Ambrilia Biopharma Inc Verbindungen auf lysinbasis
EP1877091B1 (en) 2005-04-27 2015-03-25 TaiMed Biologics, Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
JP2009517412A (ja) 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
AU2007287353A1 (en) 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors

Similar Documents

Publication Publication Date Title
JP2009517412A5 (enExample)
EP2968299B1 (en) Compounds and uses thereof for the modulation of hemoglobin
JP2017535555A5 (enExample)
JP2008523069A5 (enExample)
JP2018513876A (ja) Dnaアルキル化剤
JP2010280684A5 (enExample)
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
WO2008051873A3 (en) Phenylurea compounds as soluble epoxide hydrolase inhibitors
JPWO2014017515A1 (ja) 4−[5−(ピリジン−4−イル)−1h−1,2,4−トリアゾール−3−イル]ピリジン−2−カルボニトリルの結晶多形およびその製造方法
WO2015161781A1 (zh) 一种核苷类似物及其中间体的制备方法
KR20080008399A (ko) 비스(티오-히드라지드 아미드) 염의 합성 방법
AU2007245194A1 (en) Process for preparation of HIV protease inhibitors
JP2020519680A (ja) 4−メトキシピロール誘導体の中間体の製造方法
CA2598347A1 (en) Isoxazoline derivative and novel process for its preparation
JP2004511560A5 (enExample)
ES2401843T3 (es) Procedimiento de preparación de alfa-aminoacetales ópticamente activos
JP2018501268A (ja) チゾキサニドホスフェート及びアルカンスルホネート並びにその医薬用途
RU2019113149A (ru) Низкомолекулярные активаторы амфк
RU2007106443A (ru) Соли аммония и клатраты аммонийной соли и минеральной соли в качестве носителя и действующего начала для фармацевтическо-медицинского применения и в качестве агента фазового переноса для применения в химии
JP2007532625A5 (enExample)
JP6781030B2 (ja) L−カルノシン誘導体またはその塩、及びl−カルノシンまたはその塩の製造方法
CN109734679B (zh) 一种异硫氰酸酯和磷氮硫系阻燃剂的联合制备方法
JP2008534534A5 (enExample)
ATE419230T1 (de) Verfahren zur herstellung von 2,6-dihalo-para- trifluoromethylanilin
JP2007519685A5 (enExample)